 |
 |

Hormone Replacement Therapy and High S Phase in Breast Cancer
Melody A. Cobleigh, MD;
Frances E. Norlock, DO, MPH;
Denise M. Oleske, PhD;
Alexander Starr, MD
JAMA. 1999;281:1528-1530.
Context Prolonged postmenopausal hormone replacement therapy (HRT) is associated with increased incidence of breast cancer and, paradoxically, reduced breast cancer mortality. The biological rationale for this discrepancy has not been explored.
Objective To compare the prognostic characteristics of cancers arising in women who have used HRT with those in women who never have used HRT.
Design Prospective cohort study from December 1989 to November 1996.
Setting Teaching hospital in a large midwestern metropolitan area.
Patients Cohort of 331 postmenopausal women who presented consecutively with 349 invasive breast cancers.
Main Outcome Measures Estrogen receptor (ER) status (ER positive vs ER negative) and S phase (low vs high) for current HRT users vs never users.
Results The frequency of high S-phase fraction among cancers in women who were using HRT was markedly increased compared with that in women who had never used HRT (adjusted odds ratio [OR], 2.82; 95% confidence interval [CI], 1.04-7.66). However, the greater frequency of high S-phase fraction was limited to women with ER-positive cancers (for HRT users vs never users, OR, 5.25; 95% CI, 1.36-20.28; for ER-negative cancers in HRT users vs never users, OR, 1.08; 95% CI, 0.20-5.86).
Conclusions Use of HRT appears to stimulate growth of ER-positive but not ER-negative breast cancer as measured by S-phase fraction. The prognostic significance of high S-phase fraction in current HRT users who have ER-positive tumors is unknown.
Author Affiliations: Section of Medical Oncology (Dr Cobleigh) and Departments of Medicine (Drs Norlock and Starr), and Preventive Medicine (Dr Oleske), Rush-Presbyterian-St Luke's Medical Center, Chicago, Ill.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLE
April 28, 1999
JAMA. 1999;281(16):1557-1558.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Menopausal Hormone Therapy and Risk of Clinical Breast Cancer Subtypes
Slanger et al.
Cancer Epidemiol. Biomarkers Prev. 2009;18:1188-1196.
ABSTRACT
| FULL TEXT
Estrogen Receptor {alpha} Enhances the Rate of Oxidative DNA Damage by Targeting an Equine Estrogen Catechol Metabolite to the Nucleus
Wang et al.
J. Biol. Chem. 2009;284:8633-8642.
ABSTRACT
| FULL TEXT
Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials
Greiser et al.
Hum Reprod Update 2005;11:561-573.
ABSTRACT
| FULL TEXT
Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial
Antoine et al.
Hum Reprod 2004;19:741-756.
ABSTRACT
| FULL TEXT
Geographic Excess of Estrogen Receptor-Positive Breast Cancer
Benz et al.
Cancer Epidemiol. Biomarkers Prev. 2003;12:1523-1527.
ABSTRACT
| FULL TEXT
Prognostic Characteristics of Breast Cancer Among Postmenopausal Hormone Users in a Screened Population
Kerlikowske et al.
JCO 2003;21:4314-4321.
ABSTRACT
| FULL TEXT
Association of Regimens of Hormone Replacement Therapy to Prognostic Factors among Women Diagnosed with Breast Cancer Aged 50-64 Years
Daling et al.
Cancer Epidemiol. Biomarkers Prev. 2003;12:1175-1181.
ABSTRACT
| FULL TEXT
Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial
Chlebowski et al.
JAMA 2003;289:3243-3253.
ABSTRACT
| FULL TEXT
Relationship Between Long Durations and Different Regimens of Hormone Therapy and Risk of Breast Cancer
Li et al.
JAMA 2003;289:3254-3263.
ABSTRACT
| FULL TEXT
Soy for Breast Cancer Survivors: A Critical Review of the Literature
Messina and Loprinzi
J. Nutr. 2001;131:3095S-3108.
ABSTRACT
| FULL TEXT
Hormone Replacement in Women with a History of Breast Cancer
Pritchard
The Oncologist 2001;6:353-362.
ABSTRACT
| FULL TEXT
Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance
Clarke et al.
Pharmacol. Rev. 2001;53:25-72.
ABSTRACT
| FULL TEXT
|